Will a major hospitality publication run a feature on Ozempic menus in 2026?

TL;DR

Food media has already published dozens of GLP-1 adjacent pieces on portion sizes and cravings, but a dedicated feature on hospitality venues building menus specifically around GLP-1 users would mark the trend's formal arrival in editorial culture.

The hospitality press has covered GLP-1 tangentially since 2023, mostly in the context of portion size trends and declining alcohol sales. A full feature on Ozempic menus would require the editorial establishment to acknowledge that a large enough cohort of diners now self-identifies as GLP-1 users that operators are actively designing around their preferences. Several chefs and bartenders have begun discussing this quietly. The editorial moment has not yet arrived in a flagship publication.

The GLP-1 medication wave has already reshaped how food writers, chefs, and restaurateurs think about portion sizing, alcohol pairings, and menu architecture. By 2025, an estimated 15 to 20 million Americans were taking semaglutide or tirzepatide-class drugs, with prescriptions growing quarter over quarter. This cohort tends to eat smaller portions, feel full more quickly, and in many cases reduce or eliminate alcohol.

For a hospitality publication to run a dedicated Ozempic menu feature, several conditions need to be met simultaneously: enough operators need to be publicly talking about designing for GLP-1 guests, the editorial team needs to treat the phenomenon as culturally significant rather than niche medical, and a hospitality writer needs to find compelling enough restaurant or bar stories to anchor a feature.

Eater has come closest to this threshold with pieces on restaurant portion trends and appetite-suppression adjacent topics. Punch, which focuses on spirits and cocktails, has covered the GLP-1 effect on drinking behavior from a data and trend angle. Bon Appetit and NYT Food both run substantial service-journalism features on dining behavior shifts.

The distinction that matters for this market is specificity. A feature that mentions GLP-1 in the context of a broader wellness dining trend would not qualify. The feature must be specifically about venues or menus designed with GLP-1 users as an identifiable audience. Several hospitality operators in major US cities have quietly implemented changes; the editorial question is whether any will step forward publicly enough to anchor a flagship feature.

Frequently asked

What publications would qualify for this market?

The market specifies Eater, Punch, Bon Appetit, NYT Food section, WSJ Life & Arts, and Bloomberg Pursuits. Online-only editions of these publications qualify. A standalone newsletter or social post would not.

What would an Ozempic menu actually look like?

Smaller portions, lower-calorie preparations, non-alcoholic cocktail options presented prominently, high-protein and high-fiber dishes designed for slower digestion, and drinks formulated for guests who experience heightened alcohol sensitivity on GLP-1 drugs.

Has any restaurant publicly marketed to GLP-1 users?

As of early 2026, no major US restaurant group has publicly launched a branded GLP-1 menu. Several operators have privately adjusted portion and offering strategies. The public marketing threshold has not been crossed by any well-known brand.

Why would a publication hesitate to run this feature?

Editors may be concerned about appearing to endorse pharmaceutical intervention as a dining consideration, or about alienating readers who see GLP-1 framing as clinical rather than culinary. The editorial tension between wellness journalism and food culture is real.